WHO关于B族链球菌疾病病例确认与病例定义的孕产妇免疫接种疫苗视角
B族链球菌是导致早产儿、死胎及孕产妇疾病的重要原因,孕产妇免疫接种的GBS疫苗正在研发中。世界卫生组织召集工作组,就死胎、婴儿、孕妇及产后妇女中GBS疾病的病例确认和病例定义提供共识指导,并征求外部利益相关者反馈。在干预研究中,病例捕获和确认应基于产前招募妇女、主动随访、系统临床评估、标准化采样策略和优化实验室方法。
要点
- 疫苗效力研究的主要复合终点应包括经培养确认的死胎或婴儿侵袭性GBS疾病。
- 孕妇和产后妇女的GBS脓毒症确认病例应作为额外终点或观察性研究评估。
- 培养独立诊断试验可检测推定病例,但需进一步评估。
核心结论
- 需要标准化GBS疾病的病例定义和确认方法以支持未来孕产妇GBS疫苗试验。
- 工作组提供了死胎、婴儿、孕妇及产后妇女中GBS疾病病例确认和病例定义的共识指导。
研究设计与样本
- 世界卫生组织召集工作组提供共识指导,并征求外部利益相关者反馈。
主要发现
- 在干预研究中,病例捕获和确认应基于产前招募妇女、主动随访、系统临床评估、标准化采样策略和优化实验室方法。
- 疫苗效力研究的主要复合终点应包括经培养确认的死胎或婴儿侵袭性GBS疾病,培养自通常无菌部位(可为尸检)。
- 孕妇和产后妇女的GBS脓毒症确认病例应作为额外终点或观察性研究评估。
- 培养独立诊断试验可检测额外推定病例,但需进一步评估。
- 疫苗接种对孕产妇和新生儿GBS定植及孕产妇GBS尿路感染的效力可作为额外单独终点和/或观察性研究。
关键数值与推荐
- 确认的侵袭性GBS疾病病例需从通常无菌部位培养出GBS(可为尸检样本)。
临床怎么用
- 干预研究应采用标准化病例确认方法,包括产前招募、主动随访、系统临床评估、标准化采样和优化实验室方法。
- 疫苗效力研究的主要复合终点应包括经培养确认的死胎或婴儿侵袭性GBS疾病。
局限性
- 培养独立诊断试验检测的推定病例需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Group B Streptococcus (GBS) is an important cause of disease in young infants, stillbirths, pregnant and post-partum women. GBS vaccines for maternal immunization are in development aiming to reduce this burden. Standardisation of case definitions and ascertainment methodologies for GBS disease is needed to support future trials of maternal GBS vaccines. Considerations presented here may also serve to promote consistency in observational studies and surveillance, to better establish disease burden. The World Health Organization convened a working group to provide consensus guidance for case ascertainment and case definitions of GBS disease in stillbirths, infants, pregnant and post-partum women, with feedback sought from external stakeholders. In intervention studies, case capture and case ascertainment for GBS disease should be based on antenatal recruitment of women, with active follow-up, systematic clinical assessment, standardised sampling strategies and optimised laboratory methods. Confirmed cases of invasive GBS disease in stillbirths or infants should be included in a primary composite endpoint for vaccine efficacy studies, with GBS cultured from a usually sterile body site (may be post-mortem). For additional endpoints, or observational studies, confirmed cases of GBS sepsis in pregnant and post-partum women should be assessed. Culture independent diagnostic tests (CIDTs) may detect additional presumed cases, however, the use of these diagnostics needs further evaluation. Efficacy of vaccination against maternal and neonatal GBS colonisation, and maternal GBS urinary tract infection could be included as additional, separate, endpoints and/or in observational studies. Whilst the focus here is on specific GBS disease outcomes, intervention studies also present an opportunity to establish the contribution of GBS across adverse perinatal outcomes, including all-cause stillbirth, preterm birth and neonatal encephalopathy.
引用
- Seale AC, Baker CJ, Berkley JA, et al. Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions. Vaccine. 2019. PMID: 31303524. doi:10.1016/j.vaccine.2019.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。